Pfizer: The Patent Cliff Fears Are Overblown
Pfizer's patent cliff fears are overblown
View original →Cite asCryptoQuant has tracked the directional calls on PFE by @allka-research on Seeking Alpha since Jun 2024: not yet scored on PFE (as of Nov 18, 2026).
5 PFE calls on record, a thin history.
Relative view by default: fewer than 30 PFE calls or days on record.
Sentiment timeline shows relative sentiment within this analyst's history. A perma-bull showing 8 bullish : 2 bearish in a bear market sets that as their baseline. If you notice any errors, claim @seekingalpha:allka-research to submit corrections.
Hover the chart to read the thesis of that period · click a day to pin it
Pfizer: The Patent Cliff Fears Are Overblown
Pfizer's patent cliff fears are overblown
View original →Alnylam: Amvuttra Growth And Brezosiran Strengthen The Bull Case
View original →Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings
View original →Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs
Adding dividend yield and forward P/E, Pfizer offers one of the most appealing risk/reward profiles.
View original →Pfizer: Q2 Strength Overshadows Obesity Setbacks
Strong quarterly results, a secure dividend and a low EV/EBIT multiple make Pfizer attractive.
View original →